2001 Fiscal Year Final Research Report Summary
Effects of the CYP2D6 genetic polymorphism and environmental factors on the pharmacokinetics and pharmacodynamics of fluvoxamine
Project/Area Number |
12670921
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Psychiatric science
|
Research Institution | Yamagata University |
Principal Investigator |
OTANI Koichi Yamagata University, Professor, 医学部, 教授 (00194192)
|
Co-Investigator(Kenkyū-buntansha) |
AOSHIMA Toshiaki Yamagata University, Assistant, 医学部, 助手 (50312723)
WADA Tadashi Yamagata University, Assistant, 医学部, 助手 (70292414)
TAKAHASHI Michihiro Yamagata University, Assistant Professor, 医学部, 講師 (80282200)
|
Project Period (FY) |
2000 – 2001
|
Keywords | FLUVOXAMINE / CYP2D6 / CYP1A2 / GENETIC PLYMORHISM / PHARMACOKINETICS / PHARMOCODYNAMICS |
Research Abstract |
1) Effect of CYP1A2 inhibition by enoxacine or caffeine on the pharmacodynamics of fluvoxamine in healthy volunteers In 8 male healthy volunteers, CYP1A2 inhibition by enoxacine 200 mg/day but not by caffeine 300 mg/day strengthened sleepiness of fluvoxamine 50 mg. 2) Effects of the CYP2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino-acid in Japanese depressed patients In 49 depressed patients, the CYP2D6 genotype and CYP1A2 induction by cigarette smoking did not affect the steady-state plasma concentrations of fluvoxamine and fluvoxamino-acid. 3) Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino-acid in Japanese depressed patients In 49 depressed patients, therapeutic effect of fluvoxamine was dependent on the steady-state plasma concentrations of fluvoxamine and fluvoxamino-acid, but not related to the CYP2D6 genotype or CYP1A2 induction by cigarette smoking.
|
Research Products
(16 results)